Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for hemoglobin and hematocrit in chronic kidney disease
IRCT20251223068415N1Phase 2Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of empagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Hemoglobin level and Hematocrit level. Started Feb 2026; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20251223068415N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251223068415N1.